Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets “in order to make them lower” in the U.S., an apparent response to the Trump administration’s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as part of that effort.
The announcement is among the first moves by a major drugmaker to raise prices abroad in order to lower them in the U.S., in line with President Trump’s agenda. But it’s not clear if these actions would actually increase the amount of revenue that Lilly earns abroad, since governments and private providers that cover drugs often negotiate discounts off the list prices. Lilly did not immediately announce any new price reductions in the U.S.
Lilly said it will increase the list price of Mounjaro, which it sells for both diabetes and obesity in the U.K., from £122 to £330 at the highest dose, or roughly from $165 to $447. (In the U.S., the list price for a month’s supply of Lilly’s weight loss drug, which it sells as Zepbound in the U.S., is about $1,000.)
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
